Elizabeth Thomas Bartom

  • 920 Citations
20002023
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Education/Academic qualification

PhD, Cold Spring Harbor Laboratory

… → 2004

Fingerprint Dive into the research topics where Elizabeth Thomas Bartom is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles
Genome Medicine & Life Sciences
Genes Chemical Compounds
Neoplasms Medicine & Life Sciences
Transcription Factors Medicine & Life Sciences
Tumors Chemical Compounds
Poisons Medicine & Life Sciences
Cells Chemical Compounds
Brassinosteroids Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2017 2023

Mycobacterium Infections
Mycobacterium tuberculosis
T-Lymphocytes
NK Cell Lectin-Like Receptor Subfamily C
Vaccination
Computational Biology
Neoplasms
Histones
Peptide Elongation Factors
Mutation

Research Output 2000 2019

Cutting edge: Lymphomyeloid-primed progenitor cell fates are controlled by the transcription factor TAL1

De Pooter, R. F., Dias, S., Chowdhury, M., Bartom, E. T., Okoreeh, M. K., Sigvardsson, M. & Kee, B. L., May 15 2019, In : Journal of Immunology. 202, 10, p. 2837-2842 6 p.

Research output: Contribution to journalArticle

Hematopoietic Stem Cells
Basic Helix-Loop-Helix Transcription Factors
Transcription Factors
Stem Cells
Precursor Cell Lymphoblastic Leukemia-Lymphoma

RACK1 evolved species-specific multifunctionality in translational control through sequence plasticity within a loop domain

Rollins, M. G., Jha, S., Bartom, E. T. & Walsh, D., Jun 1 2019, In : Journal of cell science. 132, 12, jcs228908.

Research output: Contribution to journalArticle

Open Access
Protein Biosynthesis
Eukaryotic Initiation Factors
Poxviridae
5' Untranslated Regions
Ribosomes
3 Citations (Scopus)

Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia

Zhao, Z., Wang, L., Volk, A. G., Birch, N. W., Stoltz, K. L., Bartom, E. T., Marshall, S. A., Rendleman, E. J., Nestler, C. M., Shilati, J., Schiltz, G. E., Crispino, J. D. & Shilatifard, A., Jan 1 2019, In : Genes and Development. 33, 1-2, p. 61-74 14 p.

Research output: Contribution to journalArticle

Aspartate Ammonia-Lyase
Threonine
Leukemia
Casein Kinase II
Therapeutics

Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease

Qi, J., Esfahani, D. R., Huang, T., Ozark, P., Bartom, E. T., Hashizume, R., Bonner, E. R., An, S., Horbinski, C. M., James, C. D. & Saratsis, A. M., May 15 2019, In : Acta Neuropathologica Communications. 7, 1, 75.

Research output: Contribution to journalArticle

Open Access
Brain Stem Neoplasms
Tenascin
Glioma
Biomarkers
Pediatrics
5 Citations (Scopus)

The coincidence between increasing age, immunosuppression, and the incidence of patients with glioblastoma

Ladomersky, E., Scholtens, D. M., Kocherginsky, M., Hibler, E. A., Bartom, E. T., Otto-Meyer, S., Zhai, L., Lauing, K. L., Choi, J., Sosman, J. A., Wu, J. D., Zhang, B., Lukas, R. V. & Wainwright, D. A., Jan 1 2019, In : Frontiers in Pharmacology. 10, MAR, 200.

Research output: Contribution to journalArticle

Open Access
Glioblastoma
Immunosuppression
Immunotherapy
Central Nervous System
Incidence